NEW YORK (GenomeWeb) – Communicating with shareholders in a letter earlier this month, Biocept CEO Michael Nall said that the company expects to launch a pilot program this year that allows select customers to move one aspect of the firm's liquid biopsy test interpretation into their own labs.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.